Skip to main content

Articles

Dr. Harriet Feilotter appointed as Director of the Ontario Molecular Pathology Research Network

Dr. Harriet Feilotter appointed as Director of the Ontario Molecular Pathology Research Network

From: https://healthsci.queensu.ca/stories/news-announcements/dr-harriet-feil…

The Faculty of Health Sciences is pleased to announce the appointment of Dr. Harriet Feilotter as Director of the Ontario Molecular Pathology Research Network (OMPRN).

Dr. Feilotter is a Professor in the Department of Pathology and Molecular Medicine at Queen’s University. She is also Director of the Molecular Genetics Laboratory at Kingston Health Sciences Centre and Chair of the Molecular Oncology Advisory Committee at Cancer Care Ontario/Ontario Health. Dr. Feilotter has worked extensively with both OMPRN and the Ontario Institute for Cancer Research (OICR) over many years, with her expertise and leadership in molecular pathology, genetics, targeted biomarkers and informatics being critical to the success of both organizations.

As Director of OMPRN, Dr. Feilotter will provide scientific leadership for a province-wide network of pathologists and laboratory scientists collaborating to carry out high-quality cancer research with a clear potential for clinical impact, as well as bringing new educational and mentoring initiatives forward in this space. Working with other OICR programs and networks she will help to foster collaboration within the Institute and across the province, with a goal of further strengthening academic pathology across Ontario.

Dr. Feilotter takes over the role as Director of OMPRN from Dr. David LeBrun, who was OMPRN’s founding director. Dr. LeBrun is a Professor in the Department of Pathology and a Principal Investigator at the Cancer Research Institute at Queen’s School of Medicine. His vision, leadership, and his expertise has been instrumental in building the Network over the past five years.

At the same time, Dr. Feilotter is being appointed to the role of Lead, Clinical Implementation at OICR. This formalizes her existing role in working with OICR leadership to provide clinical genetics expertise to support OICR’s Ontario Pathway Towards Innovation in Cancer Care (OPTICC) project, and working with stakeholders such as Cancer Care Ontario/Ontario Health, the Ontario Ministry of Health and industry partners to promote the implementation of cancer innovations within the healthcare system.

power outage

May 26th, 5-9pm Emergency power shutdown required for Etherington Hall and Richardson Laboratory

Emergency power shutdown required for Etherington Hall and Richardson Laboratory - May 26th 5-9 pm

Holidays Fri May 21 & Mon May 24

A reminder that Friday 2021 May 21 is a Queens University COVID holiday and that Monday 2021 May 24 is Victoria Day, a Statutory Holiday.

Richardson Lab will be closed, reopening on Tuesday May 25th.

 

Tuesday, 25 May 2021, 4:00 pm – Via Zoom

M. Daria Haust Lecture - KATHLEEN BURNS, MD, PhD - Tuesday, 25 May 2021, 4:00 pm – Via Zoom

KATHLEEN BURNS, MD, PhD
Chair, Department of Pathology, Dana-Farber Cancer Institute,
Professor of Pathology Harvard Medical School
“Building and wrecking genomes”

Tuesday, 25 May 2021, 4:00 pm – Via Zoom

Dr. Kathleen Burns is the Chair of the Department of Oncologic Pathology at the Dana-Farber Cancer Institute and a
Professor of Pathology at Harvard Medical School.
She received her M.D. and Ph.D. degrees from Baylor College of Medicine and was recruited to Johns Hopkins
University School of Medicine for clinical pathology (CP) residency and hematopathology fellowship. Thereafter, she
joined the faculty at Johns Hopkins, progressed through their academic ranks to Professor, and served as the
Pathology department’s Deputy Director (Vice Chair) for Research and the institution’s Physician Scientist Training
Program (PSTP) Director until leaving for Dana-Farber in 2020.
The Burns laboratory is focused on studying mobile genetic elements in human disease. Her group was among the
first to develop a targeted method for amplifying mobile DNA insertion sites in the human genome, and they study
functional effects of inherited mobile element insertions using a combination of genetic approaches and molecular
biology. The lab has also shown that the expression of long interspersed element-1 (LINE-1) open reading frame 1
protein is a hallmark of human cancers, and that somatically-acquired LINE-1 insertions characterize cancer
genomes. Her group is currently studying consequences of this activity on cancer cell biology, and seeking avenues
to translate our understanding of this basic biology to inform approaches to diagnose and treat cancers.
Dr. Burns has first or senior authored papers in highly cited peer-reviewed journals, including Science, Cell, Nature
Medicine, Nature Structural and Molecular Biology, and Proceedings of the National Academy of Sciences. She has
authored reviews for Nature Reviews Genetics and Nature Reviews Cancer and organized several major scientific
meetings in her field. Her group has been supported by the Burroughs Wellcome Fund and multiple R01 awards
from the National Institutes of Health. She is the Scientific co-founder of Oncolinea Pharmaceuticals, Inc. a
biotechnology startup company focused on discovering new therapies for LINE-1-expressing malignancies.

Contact Barb Latimer (bal@queensu.ca) for the meeting link.